Cannabidiol/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study

Documented cannabidiol (CBD) or cannabigerol (CBG) exposure after chemotherapy was associated with a lower rate of subsequent neuropathy-related diagnoses in electronic health records. These cannabis cannabinoids are being investigated for chemotherapy-associated nerve problems, which can include numbness, tingling, and pain.

Researchers compared 83 patients with post-chemotherapy CBD/CBG exposure against 118,001 patients receiving gabapentin, pregabalin, or duloxetine. The adjusted analysis found a significantly lower hazard of later neuropathy-related diagnoses in the CBD/CBG group. A separate analysis of exposure before chemotherapy found no significant association. Records did not reliably establish cannabinoid doses, formulations, or continued use.

The findings support further investigation, but measure recorded diagnoses rather than demonstrated symptom relief or nerve recovery. Very few neuropathy events occurred in the cannabinoid group, and more patients in that group died during follow-up, potentially reducing opportunities to record neuropathy. These factors make the result an exploratory signal requiring confirmation.

“Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication of neurotoxic chemotherapy, yet effective pharmacologic options for both prevention and treatment of established painful CIPN remain limited. Non-delta-9-tetrahydrocannabinol (THC) cannabinoids and related minor cannabinoids show antinociceptive effects in preclinical CIPN models, but their real-world clinical relevance remains unclear.

Methods: We performed a retrospective secondary analysis of de-identified electronic health record (EHR) data using the TriNetX Research Network to examine whether documented cannabidiol/cannabigerol (CBD/CBG) exposure was associated with subsequent neuropathy-related diagnoses among adults receiving neurotoxic chemotherapy. Patients with neuropathy-related diagnoses on or before chemotherapy were excluded. Two Cox proportional hazards analyses were performed. The post-chemotherapy exposure analysis compared post-chemotherapy CBD/CBG exposure with post-chemotherapy exposure to gabapentin, pregabalin, or duloxetine. The pre-chemotherapy exposure analysis compared patients with documented CBD/CBG exposure within one year before chemotherapy to patients who had no documented CBD/CBG exposure during that pre-chemotherapy window. The outcome was a composite neuropathy-related diagnosis 30-365 days after the index event.

Results: In the adjusted post-chemotherapy exposure model, 83 CBD/CBG-exposed patients were compared with 118,001 active-comparator patients. Post-chemotherapy CBD/CBG exposure was associated with lower hazard of subsequent neuropathy-related diagnosis-code outcomes (Hazard ratio [HR] = 0.162, 95% confidence interval [CI] = 0.041-0.649, p = 0.010). In the adjusted pre-chemotherapy exposure model, 162 CBD/CBG-exposed patients were compared with 633,329 controls. Pre-chemotherapy CBD/CBG exposure was not significantly associated with neuropathy-related diagnosis-code outcomes (HR = 0.859, 95% CI = 0.476-1.551, p = 0.614).

Conclusions: Post-chemotherapy CBD/CBG exposure was associated with lower observed hazard of neuropathy-related diagnosis-code outcomes, whereas pre-chemotherapy exposure was not significant. These exploratory findings require cautious interpretation because of sparse exposed-arm events, EHR exposure limitations, and potential competing-risk bias.”

https://pubmed.ncbi.nlm.nih.gov/42840002

“Post-chemotherapy CBD/CBG exposure was associated with a significantly lower hazard of subsequent neuropathy-related diagnoses compared with active-comparator neuropathic-pain medications in a real-world EHR cohort. Pre-chemotherapy CBD/CBG exposure was not significantly associated with neuropathy-related outcomes. These findings should be interpreted as hypothesis-generating rather than causal and should not be considered evidence for treatment of established CIPN. Instead, they identify a post-chemotherapy exposure signal that supports continued preclinical and translational investigation of CBD/CBG and related non-THC cannabinoids in chemotherapy-associated neuropathy.”

https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2026.1945720/full

Lebanese Cannabis Oil Extract Exhibits Anticancer Effects and Induces Apoptotic Signaling and Cytoplasmic Vacuolization in Lung and Breast Cancer Cells

Lebanese cannabis oil extract induced programmed cell death and reduced cell migration in human lung and breast cancer cells grown in the laboratory. Researchers found evidence that these anticancer effects involved the intrinsic apoptotic pathway—the cell’s mitochondria-associated system for initiating its own destruction.

The study examined lung cancer (A549) and breast cancer (MDA-MB-231) cell lines, measuring cell viability, apoptosis, migration, and changes in signaling proteins. Treatment increased the pro-apoptotic protein BAX and decreased the survival-promoting protein Bcl-2. The extract also produced extensive cytoplasmic vacuolization—the formation of fluid-filled compartments within cells—and altered proteins associated with autophagy, the cellular recycling process.

These findings add to preclinical evidence that cannabis extracts can affect multiple processes involved in cancer-cell survival. By linking the extract’s effects to apoptosis and changes in cellular signaling, the study provides a foundation for further investigation of its constituents and their potential anticancer applications.

“Cannabis oil has traditionally been used in Lebanon to treat various ailments, including arthritis, diabetes, cancer, and neurological disorders.

This study investigated the anticancer effects of Lebanese Cannabis Oil Extract (COE) on human lung cancer (A549) and breast cancer (MDA-MB-231) cell lines and explored the underlying mechanisms of cytotoxicity.

COE cytotoxicity was evaluated using the MTS cell proliferation assay. Apoptosis was assessed by flow cytometry using propidium iodide (PI) and FITC-conjugated Annexin V/PI staining. Western blotting was used to determine the expression of apoptosis-related proteins and autophagy markers. Cancer cell migration was assessed using a wound-healing assay, while intracellular reactive oxygen species (ROS) were quantified using the DCFDA cellular ROS detection assay.

Results: COE showed greater selectivity toward MDA-MB-231 (IC50 = 26.7 μg/mL) and A549 (IC50 = 30.2 μg/mL) cells than rat stem cells (IC50 = 42.31 μg/mL). Phase-contrast microscopy revealed marked cytoplasmic vacuolization after 24 and 48 h of treatment. In MDA-MB-231 cells, COE significantly increased BAX, cleaved caspase-3, cytochrome c, LC3B, and p-ERK, while decreasing Bcl-2. A similar pattern was observed in A549 cells, except that increases in cleaved caspase-3 and cytochrome c were significant only at 24 h, while p62 was undetectable. COE (20 and 40 μg/mL) significantly increased apoptosis in both cell lines. Cell migration assay showed significant decrease in wound closure in the IC50/4 and IC50/2 treated groups respectively 24 h post COE treatment with A549 cells showing a more pronounced response. The results also displayed a significant decline in ROS levels in both cancer cell lines after COE treatment.

Conclusion: Our findings suggest that COE exerts anticancer effects through induction of apoptosis, with evidence supporting involvement of the intrinsic apoptotic pathway. COE treatment was also associated with alterations in autophagy-related markers, increased ERK phosphorylation, and extensive cytoplasmic vacuolization suggestive of methuosis-like morphological changes. In addition, COE did not increase intracellular ROS under the experimental conditions examined.”

https://pubmed.ncbi.nlm.nih.gov/43034904/

“Cannabis, an aromatic annual herbal plant of the Cannabaceae family, has been known since antiquity, and studied for its therapeutic benefits. The history of cannabis dates to the ancient world with its medicinal use going back about 5000 years ago.”

“Our findings indicate that Cannabis Oil Extract (COE) induces apoptotic cell death, with evidence supporting partial involvement of the intrinsic apoptotic pathway.”

https://journals.sagepub.com/doi/10.1177/15347354261509182

Chemical composition and neuroprotective activity of hemp seed aqueous extract and their chemotaxonomic significance

A water-based hemp seed extract improved cognitive performance and reduced amyloid plaques in an Alzheimer’s disease mouse model. Researchers also found neuroprotective effects from the extract and several isolated compounds in laboratory-grown PC12 cells, a cell model commonly used in neuroscience research.

Chemical analysis identified 27 compounds, including nucleosides, phenylpropanamides, alkaloids, and cyclic dipeptides. Twenty were reported in the Cannabis genus for the first time, expanding knowledge of the seed’s chemistry beyond its familiar oils and proteins.

In APP/PS1 mice, the extract improved recognition memory and reduced plaque deposition associated with Alzheimer’s pathology. These preclinical findings identify water-extracted hemp seed compounds as promising candidates for further research into neuroprotection and neurodegenerative disease.

“Fructus Cannabis (hemp seed) is important in food and traditional Chinese medicinal applications. Several studies have shown it has antioxidant, antiaging, anti-inflammatory, and neuroprotective properties.

Studies have reported its anti-Alzheimer’s disease effects. However, its active substances have not been defined, and little is known about the chemical constituents of the aqueous extract.

The chemical profile of the aqueous extract of Fructus Cannabis (EFC) was obtained via isolation, structural identification, and qualitative and quantitative analyses. Twenty-seven compounds were identified, including seven nucleosides (1–7), five phenylpropanamides (8–11, and 24), three alkaloids (15, 16, and 26), two cyclic dipeptides (17 and 25), and one pyrimidine (19). Compounds 1, 3–7, 12, 14–19, and 21–27 were not reported previously in the Cannabis genus. Therefore, their chemotaxonomic significance is discussed.

Neuroprotective activity screening revealed that EFC and the isolated compounds, particularly 9, 11, and 17, showed significant neuroprotective effects in PC12 ​cells (rat pheochromocytoma cells).

The novel object recognition experiment and Nissl staining showed that EFC improved cognitive impairment in APP/PS1 mice and that EFC intervention reduced the number of senile plaques. These findings will contribute to the utility of Fructus Cannabis.”

https://pmc.ncbi.nlm.nih.gov/articles/PMC12709937

Cannabis flower extracts as a multi-target agent in Alzheimer’s disease: Inhibition of AChE, BChE, and BACE1 with cell-protective effects in a PC12 cell model

Whole cannabis flower extracts inhibited three Alzheimer’s-related enzymes and improved cell viability under oxidative stress in laboratory experiments. The researchers studied multi-component extracts containing diverse cannabis compounds, examining their ability to act on several disease-related targets.

The extracts inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), enzymes that break down acetylcholine, a chemical messenger important for memory. They also inhibited BACE1, an enzyme involved in producing amyloid-beta. Cholinesterase inhibition exceeded that of galantamine under the tested assay conditions, with activity depending on extract composition.

Researchers also tested the extracts in PC12 cells exposed to hydrogen peroxide and amyloid-beta, finding improved viability under oxidative stress. Together, these findings identify whole cannabis flower extracts as promising candidates for investigating combined enzyme-inhibiting and cell-protective approaches to Alzheimer’s disease.

“Alzheimer’s disease (AD) is a neurodegenerative disorder marked by progressive cognitive decline. Despite extensive research, its multifactorial nature continues to challenge the development of effective therapies. Current treatments, including anticholinergic agents and amyloid β-targeted drugs, alleviate symptoms but fail to halt disease progression and often produce side effects. Therefore, novel multi-target strategies are urgently needed.

Cannabis (Cannabis sativa L.) has long been recognized for its medicinal properties, yet its potential in AD therapy has only recently gained attention. Previous studies have mainly focused on single cannabinoids or endocannabinoid system modulation.

In this study, we investigated whole cannabis flower extracts, rich in diverse active compounds, for their ability to inhibit key AD-related enzymes: acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-secretase (BACE1), using spectrophotometric assays.

Fractionation of one extract further identified components with potent inhibitory activity against both BChE and BACE1. Additionally, the extracts were evaluated for their cell-protective potential in PC12 cells exposed to hydrogen peroxide (H₂O₂) and amyloid β (Aβ₁-₄₂), mimicking AD-like oxidative stress conditions.

Cannabis extracts showed stronger inhibition of cholinergic enzymes compared to Galantamine, with efficacy depending on extract composition. Importantly, this study is among the first to reveal significant BACE1 inhibition by cannabis extracts. Moreover, the extracts enhanced PC12 cell viability under oxidative stress, indicating cell-protective effects.

Overall, these findings suggest that multi-component cannabis extracts may interact with several AD-related molecular targets in vitro and may serve as promising leads for further mechanistic and preclinical investigation.”

https://pubmed.ncbi.nlm.nih.gov/42934778

“Taken together, the study highlights the promise of cannabis inflorescence extracts, especially from Type II and III chemovars and fractions, as promising in-vitro multi-target candidates for further investigation in AD related models. By combining cholinesterase inhibition, BACE1 inhibition, and neuroprotection against oxidative and amyloid stress, cannabis-derived compounds may offer a more comprehensive approach compared to current single-target drugs.”

https://link.springer.com/article/10.1186/s42238-026-00479-9

Semi-Synthesis and Evaluation of Cannabichromene-Derived Amine and Amide Analogues as Anticancer Agents

Chemically modified compounds derived from cannabichromene (CBC), a cannabinoid found in cannabis, inhibited growth across multiple human cancer cell types in laboratory testing. Researchers synthesized a series of amine and amide analogues—modified versions of CBC—and screened them against the National Cancer Institute’s NCI-60 tumor cell panel.

Compounds 8 and 9 showed the strongest and broadest activity among the derivatives tested. Compound 9 was particularly active against PC-3 and DU-145 prostate cancer cells, inhibiting growth at low micromolar concentrations. It also induced apoptosis, the process of programmed cell death, in both prostate cancer cell lines.

The findings identify compound 9 as a promising starting point for further anticancer drug development. They highlight how CBC’s chemical structure can support the design of biologically active molecules, with further optimization and investigation needed to establish how these derivatives work.

“A novel series of cannabichromene-derived amine and amide analogues (4-13) was synthesized and evaluated for their anticancer activity against the NCI-60 human tumor cell line panel.

Among the synthesized derivatives, compounds 8 and 9 demonstrated the most potent and broad-spectrum anticancer activities, exhibiting significant percent growth inhibition across multiple cancer subtypes. Notably, compound 9 displayed good potency in prostate cancer cell lines PC-3 and DU-145, with GI50 values of 2.01 μM and 1.86 μM, respectively and pronounced cytotoxicity at higher concentrations. Its consistent performance across diverse cancer panels suggests a non-selective yet potent mechanism, likely targeting essential cellular pathways common to malignant cells. Compound 9 was found to induce apoptosis in PC-3 and DU-145 cells.

Collectively, these findings highlight 9 as a promising compound for further optimization and mechanistic exploration towards developing new anticancer leads derived from the cannabichromene scaffold.”

https://pubmed.ncbi.nlm.nih.gov/42924954

“In summary, the CBC amide analogues, particularly compounds 8 and 9, demonstrated significant anticancer potential across multiple NCI-60 cancer cell lines, exhibiting broad-spectrum cytotoxic activity.”

https://pubs.acs.org/jnprdf/article/89/10/2827/5442683/Semi-Synthesis-and-Evaluation-of-Cannabichromene

Hemp seed oil ameliorates DSS-induced ulcerative colitis in mice by altering transcriptomics and metabolomics

Hemp seed oil reduced disease activity, lowered inflammatory cytokines, and improved colon tissue findings in mice with experimentally induced ulcerative colitis. Researchers combined gene-expression and metabolic analyses to investigate how the oil influenced inflammation and intestinal protection.

Treatment suppressed IL-6, IL-1β, and IL-17, while gene-expression analysis indicated reduced IL-17 and TNF inflammatory signaling. It also increased expression of ZO-1 and occludin, proteins that help maintain the intestinal barrier by keeping neighboring cells tightly connected.

Researchers identified 19 altered colon metabolites associated with amino acid metabolism, energy balance, and lipid signaling. These preclinical findings suggest that hemp seed oil acts on interconnected metabolic and inflammatory processes, supporting further investigation of its therapeutic potential for inflammatory bowel disease.

“Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with complex pathogenesis and limited treatments.

Hemp seed oil, with its unique ω-6/ω-3 polyunsaturated fatty acid ratio and phenolic antioxidants, exhibits anti-inflammatory and gut barrier-enhancing properties, though its mechanisms in UC are not fully understood.

Here, we applied an integrated transcriptomics and metabolomics approach to investigate the effects of hemp seed oil in dextran sulfate sodium (DSS)-induced UC mice.

Treatment with hemp seed oil (1 g/kg) significantly alleviated disease activity, suppressed proinflammatory cytokine levels (interleukin (IL)-6, IL-1β, and IL-17), and improved colonic histopathology. Metabolomic profiling via ultrahigh-performance liquid chromatography-quadrupole-orbitrap tandem mass spectrometry (UPLC-Q-Orbitrap MS/MS) identified 19 significantly altered colonic metabolites, predominantly involved in amino acid metabolism, energy homeostasis, and lipid signalling pathways.

Transcriptomic analysis suggested that hemp seed oil treatment was associated with inhibition of the IL-17 and tumor necrosis factor (TNF) signalling pathways while upregulating genes involved in barrier function (e.g., zonula occludens-1 (ZO-1) and Occludin). Integrative analysis revealed strong inverse correlations between key metabolites (e.g., docosahexaenoic acid ethyl ester, adenosine diphosphate (ADP)) and IL-17 pathway activation (IL17A, C-X-C motif chemokine ligand 10 (CXCL10)), suggesting that hemp seed oil may attenuate UC through reprogramming the “metabolism‒inflammation” axis.

These findings suggest potential multitarget therapeutic mechanisms of hemp seed oil against UC, indicate critical links between metabolic reprogramming and the immune‒inflammatory axis, and offer novel insights for the development of phytomedicine for the treatment of inflammatory bowel disease.”

https://pubmed.ncbi.nlm.nih.gov/42766258/

https://link.springer.com/article/10.1007/s11418-026-02082-x

Cannabis sativa phytoligands as potential EGFR inhibitors for lung cancer treatment

Compounds found in Cannabis sativa showed promising predicted binding to epidermal growth factor receptor (EGFR), a protein that promotes tumour-cell proliferation when overexpressed. Using computer-based screening, researchers identified luteolin-7-O-glucoside, grossamide, and quercetin as leading candidates for blocking the receptor’s kinase domain—a target in lung cancer treatment.

During 100-nanosecond molecular dynamics simulations, quercetin formed the most structurally stable EGFR complex. Grossamide produced the most favourable calculated binding free energy, exceeding the reference drug gefitinib in this computational measure. The leading compounds also showed favourable predicted pharmacokinetic profiles.

These findings highlight cannabis plant compounds as candidates for developing therapies that target EGFR.

“Lung cancer remains a major global health burden, and epidermal growth factor receptor (EGFR) overexpression promotes tumour-cell proliferation, making EGFR an important therapeutic target.

This study used an in-silico approach to evaluate Cannabis sativa compounds as inhibitors of the EGFR kinase domain.

Among the compounds investigated, Luteolin-7 -O- glucoside, grossamide, and quercetin were the leading ATP-competitive inhibitors, with binding affinities of -10.878, -10.091, and – 10.000 kcal/mol, respectively. A four-feature pharmacophore model was generated from the lead compounds, which also showed favourable predicted pharmacokinetic profiles.

During 100-ns molecular dynamics simulations (MDS), the EGFR-quercetin complex exhibited the lowest root mean square deviation of 0.9-1.5 Å, while fluctuation profiles revealed a relatively stable ligand-bound complex compared with the apo-EGFR. The MDS trajectory Molecular Mechanics/Generalized Born Surface Area analysis yielded binding free energies of -75.59 kcal/mol for grossamide, -56.90 kcal/mol for isovitexin, -49.11 kcal/mol for luteolin-7 -O- glucoside, and – 43.27 kcal/mol for quercetin, compared with – 47.41 kcal/mol for gefitinib. Electronic profiling revealed favourable orbital overlap and softness for quercetin and flavone glycosides within EGFR, while isovitexin showed superior kinetic stability and balanced solvation, supporting strong binding and active-site entry.

These findings identify luteolin-7 -O- glucoside, grossamide, and quercetin as promising EGFR inhibitors and provide a baseline hypothesis for experimental validation.”

https://pubmed.ncbi.nlm.nih.gov/42999331

https://www.researchsquare.com/article/rs-11024152/v1

Direct evidence for psychoactive cannabis use 2800 years ago

Chemical traces in human hair from a burial mound in southern Siberia provide the oldest directly dated evidence that people used cannabis for its mind-altering effects. The findings, published in Science, place psychoactive cannabis use at least 2,800 years ago.

At the Tunnug 1 burial mound, researchers radiocarbon-dated six cannabis seeds, placing them in the early eighth century BCE. High-resolution mass spectrometry detected clear signals consistent with cannabinol (CBN), which can form as THC oxidizes, in several hair samples. The researchers also found weaker signals consistent with THC itself.

The seeds establish that cannabis was placed in the tomb. The chemical traces in the hair are what led researchers to conclude that people likely used it for its psychoactive effects. The analysis leaves open how much they used and whether they inhaled or ingested it.

“Cannabis is the world’s most-used illicit psychoactive plant, yet direct prehistoric evidence for its consumption is rare. In this study, we present the earliest direct evidence of cannabis use: offerings of plant parts and chemical compounds in ancient human hair recovered from a monumental tomb in Siberia.

The findings suggest that the plant was used for its psychoactive qualities across Eurasia, where specific wild populations might have had naturally higher active compound levels. We show that the practice of cannabis consumption dates back at least 2800 years, anchoring debates around contemporary usage and informing discussions on cannabis in medicine, public health, law, and industry.”

https://pubmed.ncbi.nlm.nih.gov/42986939

“Psychoactive plants are used globally today, with increasing evidence of medicinal value and, in some cases, decreasing illegality. Cannabis is one of the most widely used and cultivated of these plants. The prevalence of past usage, particularly for ritual purposes, has often been suggested, but making conclusions about its use for psychoactive properties has been difficult. Cannabis plants are ephemeral, and even the presence of plant parts and seeds could be an indication of cultivation for its many other useful properties. Caspari et al. found cannabis plant parts in a 2800-year-old tomb in Siberia and also identified its psychoactive compounds in hair found within the tomb, suggesting ritualistic psychoactive use.”

https://www.science.org/doi/10.1126/science.aeg3800

Efficacy of dietary hempseed oil in patients with atopic dermatitis

Dietary hempseed oil improved skin dryness and itching and reduced the use of skin medications in patients with atopic dermatitis, commonly called eczema. Researchers compared hempseed oil with olive oil in a 20-week randomized, single-blind crossover trial, examining symptoms, blood fatty acid profiles, and moisture loss through the skin.

After hempseed oil consumption, blood levels of linoleic acid, alpha-linolenic acid, and gamma-linolenic acid increased. Patients reported significant improvements in dryness and itching, along with reduced medication use. Skin moisture loss also decreased, although that change did not reach statistical significance.

The authors suggested that the symptom improvements resulted from hempseed oil’s abundant, balanced supply of polyunsaturated fatty acids. These human clinical findings support the therapeutic potential of dietary hempseed oil for eczema and highlight the value of cannabis seeds beyond their basic nutritional benefits.

“Background: Hempseed oil is a rich and balanced source of omega-6 and omega-3 polyunsaturated fatty acids (PUFAs). Anecdotal evidence indicated that dietary hempseed oil might be useful in treating symptoms of atopic dermatitis.

Patients and methods: Dietary hempseed oil and olive oil were compared in a 20-week randomized, single-blind crossover study with atopic patients. Fatty acid profiles were measured in plasma triglyceride, cholesteryl and phospholipid fractions. A patient questionnaire provided additional information on skin dryness, itchiness and usage of dermal medications. Skin transepidermal water loss (TEWL) was also measured.

Results: Levels of both essential fatty acids (EFAs), linoleic acid (18:2n6) and alpha-linolenic acid (18:3n3), and gamma-linolenic acid (GLA; 18:3n6) increased in all lipid fractions after hempseed oil, with no significant increases of arachidonic acid (20:4n6) in any lipid fractions after either oil. Intra-group TEWL values decreased (p=0.074), qualities of both skin dryness and itchiness improved (p=0.027) and dermal medication usage decreased (p=0.024) after hempseed oil intervention.

Conclusions: Dietary hempseed oil caused significant changes in plasma fatty acid profiles and improved clinical symptoms of atopic dermatitis. It is suggested that these improvements resulted from the balanced and abundant supply of PUFAs in this hempseed oil.”

https://pubmed.ncbi.nlm.nih.gov/16019622

https://www.tandfonline.com/doi/abs/10.1080/09546630510035832

Optimal cannabinoid-terpene combination ratios suppress mutagenicity of gastric reflux in normal and metaplastic esophageal cells

Cannabigerol (CBG) paired with selected plant compounds reduced reflux-related DNA damage in laboratory models of the human esophagus. Researchers tested cannabinoid–terpene combinations in normal esophageal cells and Barrett’s esophagus cells, which represent changes associated with increased esophageal cancer risk.

A combination of CBG and phytol—a plant-derived terpenoid—at a 1:5 ratio showed particular promise. It reduced bile-acid-induced DNA damage and oxidative stress, helped maintain mitochondrial function, and encouraged damaged cells to undergo programmed cell death. The researchers also reported reduced mutagenicity, suggesting protection against changes that can contribute to cancer development.

These findings identify cannabinoid–terpene ratios worth investigating for protection against reflux-related cellular injury. The results come from cell experiments; animal studies and clinical trials are needed to determine whether these combinations could benefit people with reflux or Barrett’s esophagus.

“Background: Esophageal adenocarcinoma (EAC) frequently arises from chronic exposure to acid and bile reflux, with secondary bile acids, such as deoxycholic acid (DCA), contributing to its pathogenesis through mechanisms involving reactive oxygen species (ROS), oxidative DNA damage, and resistance to apoptosis. The human endocannabinoid system (ECS) regulates diverse anti-inflammatory, antioxidant, and analgesic pathways implicated in disease modulation and may counteract the harmful effects of gastroesophageal reflux. Despite its therapeutic promise, effective pharmacological activation of the ECS remains challenging.

Aim: To evaluate whether specific cannabinoid-terpene combinations targeting the ECS could attenuate the mutagenic and cytotoxic effects of bile acid-induced stress in esophageal cell models, and to assess the clinical significance of ECS-related protein receptors in the progression of EAC.

Methods: Human esophageal epithelial cells exposed to DCA, as well as a Barrett’s esophagus cell line subjected to low potential of hydrogen and a bile acid cocktail, were treated with various ratios of phyto-cannabinoids and terpenes. Endpoints included DNA damage, mitochondrial membrane potential, and ROS production to identify optimal compound combinations. Expression of ECS-related receptor proteins in clinical samples was assessed by immunohistochemistry.

Results: A 1:5 ratio of cannabigerol to phytol significantly reduced DCA-induced DNA damage, preserved mitochondrial membrane potential, and decreased ROS levels. This combination also promoted apoptosis in damaged cells and reduced mutagenicity. Analysis of patient samples demonstrated that expression of the ECS-associated receptor protein CB1 correlated with EAC progression, indicating a broader clinical role for ECS modulation in cancer prevention.

Conclusion: Modulation of the ECS using systematically selected cannabinoid-terpene ratios can attenuate bile acid-induced esophageal damage and may reduce carcinogenic progression. These findings support further in vivo studies and raise the possibility of expanding cannabinoid-terpene therapeutics to other diseases with comparable pathogenic mechanisms.”

https://pubmed.ncbi.nlm.nih.gov/42829479

“The combination of CBG and terpenes may offer novel cancer prevention strategies to address the increasing incidence of esophageal cancer, a disease lacking effective treatment options.”

https://www.wjgnet.com/1007-9327/full/v32/i14/111455.htm